Genetically modeled GLP1R and GIPR agonism reduce binge drinking and alcohol-associated phenotypes: a multi-ancestry drug-target Mendelian randomization study.

Reitz, Joshua et al.·Molecular psychiatry·2025·Moderate Evidencemendelian-randomization
RPEP-13235Mendelian RandomizationModerate Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
mendelian-randomization
Evidence
Moderate Evidence
Sample
N=Large GWAS datasets (specific N varies by outcome)
Participants
Multi-ancestry populations from genome-wide association studies

What This Study Found

Genetic variants mimicking GLP-1 and GIP receptor activation were linked to reduced binge drinking and heavy drinking with psychiatric comorbidities, but showed no effect on tobacco, cannabis, or opioid use disorders.

Key Numbers

Binge drinking: beta = -0.44 (95% CI -0.72 to -0.15, p = 0.0024). Heavy drinking with psychiatric comorbidities: OR = 0.62 (95% CI 0.45-0.85, p = 0.0031). NAFLD: beta = -0.34 (p = 0.0000274). No significant effects on tobacco, cannabis, or opioid use.

How They Did This

Drug-target Mendelian randomization using genetic variants at GLP1R and GIPR loci. Multi-ancestry analysis. Multiple MR methods and colocalization analyses for robustness. Mediation analysis for cardiovascular effects.

Why This Research Matters

This genetic approach simulates the long-term effects of GLP-1/GIP drugs and suggests they may specifically reduce problematic alcohol use through appetite and metabolic pathways, not through a general effect on all addictive behaviors.

What This Study Doesn't Tell Us

Genetic proxies simulate lifetime exposure, not short-term drug treatment. Cannot determine optimal dose or duration. Population-level estimates may not apply to individual patients. Observational genetic design cannot fully prove causation.

Trust & Context

Original Title:
Genetically modeled GLP1R and GIPR agonism reduce binge drinking and alcohol-associated phenotypes: a multi-ancestry drug-target Mendelian randomization study.
Published In:
Molecular psychiatry, 30(12), 6119-6133 (2025)
Database ID:
RPEP-13235

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Cite This Study

RPEP-13235·https://rethinkpeptides.com/research/RPEP-13235

APA

Reitz, Joshua; Rosoff, Daniel B; Perlstein, Tyler; Wagner, Alexandra; Jung, Jeesun; Wagner, Josephin; Reiner, Benjamin C; Lohoff, Falk W. (2025). Genetically modeled GLP1R and GIPR agonism reduce binge drinking and alcohol-associated phenotypes: a multi-ancestry drug-target Mendelian randomization study.. Molecular psychiatry, 30(12), 6119-6133. https://doi.org/10.1038/s41380-025-03199-3

MLA

Reitz, Joshua, et al. "Genetically modeled GLP1R and GIPR agonism reduce binge drinking and alcohol-associated phenotypes: a multi-ancestry drug-target Mendelian randomization study.." Molecular psychiatry, 2025. https://doi.org/10.1038/s41380-025-03199-3

RethinkPeptides

RethinkPeptides Research Database. "Genetically modeled GLP1R and GIPR agonism reduce binge drin..." RPEP-13235. Retrieved from https://rethinkpeptides.com/research/reitz-2025-genetically-modeled-glp1r-and

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.